Promotion
This page lists 302 references in the Main Healthy Skepticism Library relevant to Promotion.
Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text.
HSL6397
Wilksch SM, Tiggemann M, Wade TD.
Impact of interactive school-based media literacy lessons for reducing internalization of media ideals in young adolescent girls and boys.
Int J Eat Disord 2006 Jul 01;39(5):385-93
Link to source with long URL
HSL5616
Silversides A.
Monitoring the price of new drugs.
CMAJ 2006 May 23;174(11):1548-9
Link to source with long URL
HSL2681
Zoutman D E, Ford BD, Bassili AR
Prescription data
Canadian Medical Association Journal 2006 May 01;164(10):1410-1409
HSL6105
Grace M.
Ethical marketing.
Br Dent J 2006 Apr 22;200(8):418
http://www.nature.com/doifinder/10.1038/sj.bdj.4813532
HSL5771
Harvie J.
Rebels with a cause: The constant campaigner
Australian Doctor 2006 Mar 31:20
HSL5571
Cardarelli R, Licciardone JC, Taylor LG.
A cross-sectional evidence-based review of pharmaceutical promotional marketing brochures and their underlying studies: is what they tell us important and true?
BMC Fam Pract 2006 Mar 3;7(13)
http://www.biomedcentral.com/1471-2296/7/13
HSL5673
Chan CH.
The pharmaceutical role.
Acad Psychiatry 2006 Jan-Feb 01;30(1):45-7
http://ap.psychiatryonline.org/cgi/content/full/30/1/45
HSL5686
Skiba M.
Strategies for identifying and minimizing medication errors in health care settings.
Health Care Manag (Frederick) 2006 Jan-Mar 01;25(1):70-7
Link to source with long URL
HSL4035
Huang F, Et AL.
The Association of Pharmaceutical Company Promotional Spending With Resident Physician Prescribing Behavior
Academic Psychiatry 2005 Dec 1(29):500-501
http://ap.psychiatryonline.org/cgi/content/full/29/5/500
HSL3895
Day M.
How the Media caught Tamiflu
BMJ 2005 Nov 26;331:1277
http://bmj.bmjjournals.com/cgi/content/full/331/7527/1277
HSL3942
Mansfield PR.
Banning all drug promotion is the best option pending major reforms.
J Bioethical Inquiry 2005;2(2):16-22
HSL4056
Burton B
US drug industry's guidelines on advertising too limited, say critics.
BMJ 2005 Aug 20;331(7514):420
Link to source with long URL
HSL2732
Sharfstein SS.
Big Pharma and American Psychiatry: The Good, the Bad, and the Ugly.
Psychiatric News 2005 Aug 19;40(16):3
http://pn.psychiatryonline.org/cgi/content/full/40/16/3
HSL4053
Croll TP, Swanson BZ Jr19th century dentistry.
Advertising trade cards.
J Hist Dent 2005 Jul 01;53(2):62
HSL1929
Avorn J.
Torcetrapib and atorvastatin--should marketing drive the research agenda?
N Engl J Med 2005 Jun 23;352(25):2573-6
http://content.nejm.org/cgi/content/extract/352/25/2573
HSL1915
Jackson L.
A marketing breakthrough
Mediawatch ABC Online 2005 Jun 13
http://www.abc.net.au/mediawatch/transcripts/s1390967.htm
HSL1907
Words to the wise healthcare consumer: Approach with caution
2005 Jun 8
HSL1724
Burton B.
Pfizer Australia is fined for misleading promotion of celecoxib
BMJ 2005 May 28;330:1230
http://bmj.bmjjournals.com/cgi/content/full/330/7502/1230-b
HSL1775
Appleby J.
Merck's marketing of Vioxx called misleading
USA TODAY 2005 May 6
http://www.usatoday.com/printedition/money/20050506/vioxx06.art.htm
HSL2129
Stanley AG, Jackson D, Barnett DB.
The teaching of drug development to medical students: collaboration between the pharmaceutical industry and medical school.
Br J Clin Pharmacol 2005 Apr;59(4):464-74
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2125.2005.02374.x
HSL1168
Raven M, Rogers W, Jureidini J.
Partnerships between academic psychiatry and the pharmaceutical industry.
Australas Psychiatry 2005 Mar;13(1):83-4
Link to source with long URL
HSL1890
Mansfield PR.
Beliefs and plans of GP registrars before and after a 90 minute talk about drug promotion
Unpublished 2005 Feb 25
HSL1931
Mohl PC.
Psychiatric training program engagement with the pharmaceutical industry: an educational issue, not strictly an ethical one.
Acad Psychiatry 2005 Sum;29(2):215-21
http://ap.psychiatryonline.org/cgi/content/full/29/2/215
HSL1897
Douglas KM, Sutton RM.
Right about others, wrong about ourselves? Actual and perceived self-other differences in resistance to persuasion
Br J Soc Psychol 2004 Dec;43(Pt 4):585-603
Link to source with long URL
HSL2143
Bellin M, McCarthy S, Drevlow L, Pierach C.
Medical students' exposure to pharmaceutical industry marketing: a survey at one U.S. medical school.
Acad Med. 2004 Nov;79(11):1041-5. 2004 Nov 01;79(11):1041-5
http://www.academicmedicine.org/cgi/content/full/79/11/1041
HSL487
Mansfield PR, Henry D.
Misleading drug promotion--no sign of improvements.
Pharmacoepidemiol Drug Saf 2004 Nov;13(11):797-9
http://www3.interscience.wiley.com/cgi-bin/abstract/107632790/ABSTRACT
HSL2210
Huh J, Cude BJ.
Is the information "fair and balanced" in direct-to-consumer prescription drug websites?
J Health Commun 2004 Nov-Dec;9(6):529-40
Link to source with long URL
HSL1889
Mansfield PR.
A 5 minute read re drug promotion: RCT
Poster presented at 8th World Congress on Clinical Pharmacology & Therapeutics (CPT2004) Brisbane 2004 Aug 1-6
HSL1351
Watkins RS, Kimberly J Jr.
What residents don't know about physician-pharmaceutical industry interactions.
Acad Med 2004 May;79(5):432-7
http://www.academicmedicine.org/cgi/content/full/79/5/432
HSL245
Gulhati CM.
Marketing of medicines in India.
BMJ 2004 Apr 3;328(7443):778-9
http://bmj.bmjjournals.com/cgi/content/full/328/7443/778
HSL266
Zoutman DE, Ford BD, Bassili AR.
The confidentiality of patient and physician information in pharmacy prescription records.
CMAJ 2004 Mar 2;170(5):815-6
http://www.cmaj.ca/cgi/content/full/170/5/815
HSL1458
Cathebras P.
[Doctor Knock lives at Wall Street. The new targets of pharmaceutical industry]
Rev Med Interne 2003 Aug;24(8):538-41
HSL1415
Ma J, Stafford R, Cockburn I, Finkelstein S.
A statistical analysis of the magnitude and composition of drug promotion in the United States in 1998
Clin Ther 2003 May;25(5):1503-17
Link to source with long URL
HSL2100
Zimmerman HM.
Rx for compliance. How the new PhRMA code on permissible pharmaceutical marketing practices affects your organization
MGMA Connex. 2003 Feb 01;3(2):54-7, 1.
HSL1446
Dubois RW.
Pharmaceutical promotion: don't throw the baby out with the bathwater.
Health Aff (Millwood) 2003 Jan-Jun;Suppl
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.96v1
HSL1472
Batchlor E, Laouri M.
Pharmaceutical promotion, advertising, and consumers.
Health Aff (Millwood) 2003 Jan-Jun;Suppl
http://content.healthaffairs.org/cgi/reprint/hlthaff.w3.109v1
HSL1460
Carter T.
Pfizer and its competitive marketing challenges.
J Hosp Mark Public Relations 2003;14(2):85-97
HSL2396
Kay J.
The Truth about Markets: Why Some Nations are Rich but Most Remain Poor
London: Penguin Books; 2003
http://www.penguin.co.uk/nf/Book/BookDisplay/0,,0_0140296727,00.html
HSL2139
Hensley S.
When doctors go to class, industry often foots the bill: lectures tend to feature pills made by course sponsors; companies deny influence; a purple heartburn brochure.
Wall St J (East Ed) 2002 Dec 4;:A1,
HSL556
Brodie M, Levitt L.
Drug advertising: the right or wrong prescription for our ailments?
Nat Rev Drug Discov 2002 Nov;1(11):916-20
Link to source with long URL
HSL2217
Brotons C, Moral I, Ribera A, Cascant P, Iglesias M, Permanyer-Miralda G, Ferreira Gonzalez I, Soler-Soler J.
[Methods of reporting research-results and their influence on decision-making by cardiologists prescribing drugs for primary and secondary prevention.]
Rev Esp Cardiol 2002 Oct;55(10):1042-51
Link to source with long URL
HSL2448
Fugh-Berman A, Pearson C.
The overselling of hormone replacement therapy.
Pharmacotherapy 2002 Sep;22(9):1205-8
HSL1893
Sagarin BJ, Cialdini RB, Rice WE, Serna SB.
Dispelling the illusion of invulnerability: the motivations and mechanisms of resistance to persuasion.
J Pers Soc Psychol 2002 Sep;83(3):526-41
http://content.apa.org/journals/psp/83/3/526
HSL2261
Stewart KA, Neumann PJ.
FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation.
Value Health 2002 Sep-Oct;5(5):389-96
Link to source with long URL
HSL3097
Questions of interest
Canadian Medical Association Journal 2002 Feb 19;166(4):413
HSL2903
Berkowitz BA, Sachs G.
Life Cycle of A Block Buster Drug: Discovery and Development of Omeprazole (PrilosecTM)
Mol Interv 2002 Feb;2(1):6-11
Link to source with long URL
HSL2895
Calfee JE.
The role of marketing in pharmaceutical research and development.
Pharmacoeconomics 2002;20
Link to source with long URL
HSL2905
Baird PA.
Identification of genetic susceptibility to common diseases: the case for regulation.
Perspect Biol Med 2002 Fal;45(4):516-28
Link to source with long URL
HSL4285
Is Yasmin a "truly different" pill?
Drug Ther Bull 2002;40(8):57-9
Link to source with long URL
HSL2947
Reidenberg , M .
Releasing the grip of big pharma (1st of 3 letters)
Lancet 2001 Aug 25;358:664
HSL2682
Zitner D.
Prescription data
Canadian Medical Association Journal 2001 May 15;164(10):1408-1409
HSL2697
Short , S .
Prescription data
CMAG 2001 May 15;164(10):1408
HSL2919
Sukkari S, Sasich , L .
Cisapride and patient information leaflets (1st of 4 letters)
Canadian Medical Association Journal 2001 May 1;164(9):1276-1278
HSL2981
Arnott W.
Cisapride and patient information leaflets (2nd of 4 letters)
Canadian Medical Association Journal 2001 May 1;164(9):1278
HSL121
Stout E.
Doctoring sales
Sales & Marketing Management 2001 May:52-60
Nil
HSL2741
Lal A.
Pharmaceutical drug promotion: how it is being practiced in India?
J Assoc Physicians India 2001 Feb;49:266-73
HSL2459
Norman GR.
The epistemology of clinical reasoning: perspectives from philosophy, psychology, and neuroscience.
Acad Med 2000 Oct;75(10)
Link to source with long URL
HSL1766
Cialdini RB.
Influence: Science and Practice 4th Edn
New York: Allyn & Bacon; 2000
http://www.ablongman.com/catalog/academic/product/0,1144,0321011473,00.html
HSL8519
Letendre W, Jackson R.
Marketing your prescription compounding practice. Part 3
International Journal of Pharmaceutical Compounding 2000;4(3):199-202
HSL2159
Slawson DC, Shaughnessy AF.
Teaching information mastery: creating informed consumers of medical information.
J Am Board Fam Pract 1999 Nov-Dec;12(6):444-9
HSL2140
Razack S, Arbour L, Hutcheon R.
Proposed model for interaction between residents and residency training programs, and pharmaceutical industry.
Ann R Coll Physicians Surg Can 1999 Mar;32(2):93-6
HSL549
Day R.
Pharmaceutical company promotion: striking a balance.
Aust N Z J Med 1998 Jun;28(3):291-3
Nil
HSL530
Lexchin J.
[Pharmaceutic regulation and inadequate drug prescription in Canada: the case of psychotropic drugs in the 1960s and early 1970s]
Sante Ment Que. 1997 Spring;22(1):283-300
Nil
HSL745
Wolfe SM.
Why do American drug companies spend more than $12 billion a year pushing drugs? Is it education or promotion? Characteristics of materials distributed by drug companies: four points of view
J Gen Intern Med. 1996 Oct 01;11(10):637-9
HSL747
Vitry A, Mansfield P.
Promotion of Coversyl by Servier.
Lancet 1996 May 18;347(9012):1411
HSL792
Frankel DH.
Servier criticised in perindopril campaign
Lancet 1996 Jan 20;347:183
HSL749
Van DER, S , Whyte SR, Hardon A.
The anthropology of pharmaceuticals: a bibliographical approach
Annual Review of Anthropology 1996;25:155-178
HSL775
Lewis S.
Selling guidelines door to door.
CMAJ 1996;154:756
http://www.cma.ca/cmaj/vol-154/0755e.htm
HSL795
Fisher S.
Hanky-panky in the pharmaceutical industry
International Journal of Psychopathology, Psychopharmacology and Psychotherapy 1996;1(1)
HSL1716
Barton SB, Walley T.
Bayer promotional publications misleading about effect of ciprofloxacin on hospital admissions.
Lancet 1995 Oct 21;346(8982):1102
HSL856
Cooper RS.
Risks and benefits of calcium antagonists.
Lancet 1995 Oct 7;346(8980):961
HSL843
Horton R.
Spinning the risks and benefits of calcium antagonists.
Lancet 1995 Sep 2;346(8975):586-7
HSL844
Hodges B.
Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks.
CMAJ 1995 Sep 1;153(5):553-9
HSL831
Mossinghoff GJ.
Drug promotion.
N Engl J Med 1995 Apr 13;332(15):10
HSL841
Kalish RS.
Drug promotion.
N Engl J Med 1995 Apr 13;332(15):1032
HSL845
Hoberman D.
Drug promotion.
N Engl J Med 1995 Apr 13;332(15):1031
HSL858
Cohen SN.
Drug promotion.
N Engl J Med 1995 Apr 13;332(15):1032
HSL498
Lexchin J.
Deception by design: Pharmaceutical promotion in the Third World
Penang: Consumers International; 1995
Nil
HSL848
Guyatt G.
L’enseignement de la médeicne et l’ industrie pharmaceutique
CMAJ 1995;152:1039-1040
HSL1717
Barnett AA.
FDA scrutinises drug firms’ new connections
Lancet 1995;346:1151
HSL2160
Ekedahl A, Andersson SI, Hovelius B, Molstad S, Liedholm H, Melander A.
Drug prescription attitudes and behaviour of general practitioners. Effects of a problem-oriented educational programme
Eur J Clin Pharmacol 1995;47(5):381-7
HSL7054
Stern RS.
Drug promotion for an unlabeled indication--the case of topical tretinoin.
N Engl J Med 1994 Nov 17;331(20):1348-9
http://content.nejm.org/cgi/content/extract/331/20/1348
HSL7047
Shaughnessy AF, Slawson DC, Bennett JH.
Separating the wheat from the chaff: identifying fallacies in pharmaceutical promotion.
J Gen Intern Med 1994 Oct;9(10):563-8
Nil
HSL2178
Mantyranta T, Hemminki E.
Medical students and drug promotion.
Acad Med 1994 Sep;69(9):736
HSL6600
Guyatt , G .
Relations with the pharmaceutical industry
Canadian Medical Association Journal 1994;151:415
HSL6729
Mansfield PR.
MaLAM: encouraging trustworthy drug promotion
Essential Drugs Monitor 1994(17):6
HSL6069
Vinson DC, McCandless B, Hosokawa MC.
Medical students' attitudes toward pharmaceutical marketing: possibilities for change.
Fam Med 1993 Jan;25(1):31-3
HSL2141
Ranwella S.
Sri Lankan students campaign for rational medicine: the story of SIRHA.
Essent Drugs Monit 1993(16):10
HSL5176
Collier J, Fox R.
WHO seeks ways to improve control of drug promotion
Lancet 1993;341:1017
HSL5183
Dixon , T .
Physicians and drug companies interact
Canadian Family Physician 1993;39:1882
HSL5131
Scanlan C .
Unsafe drugs find buyers abroad
MaLAM International Newsletter 1992 Oct 1:3-6
HSL4989
Preuss K.
New approaches to promotion in the EC
Scrip Magazine 1992 Oct(8):23-26
HSL4979
Darbourne A.
Pharmaceuticals in the Third World—progress or crisis?
Scrip Magazine 1992 Jul-Aug(6):6-8
HSL4975
Cowley G.
Not what the doctor ordered: a study criticizes drug ads in medical journals
Newsweek 1992 Jun 9:54
HSL4974
Jones DC.
Pricing and promotion come under scrutiny
Scrip Magazine 1992 Jun(5):16-18
www.pjbpubs.co.uk/scrip/scrhome.html
HSL4788
Bartone N.
The role of marketing research during drug development
Journal of Drug Issues 1992;22:295-303
HSL4813
Data JL, Barton KS.
Advertising baldly to the public
New England Journal of Medicine 1992;326:330-331
HSL4825
Gans JA.
The need for guidelines in pharmaceutical promotion: A pharmacy perspective
Journal of Pharmaceutical Marketing & Management 1992;7(1):147-155
HSL4842
Keith A.
The benefits of pharmaceutical promotion: An economic and health perspective
Journal of Pharmaceutical Marketing & Management 1992;7(1):121-133
HSL4866
Mossinghoff GJ.
Pharmaceutical manufacturers and self-regulation of drug advertising and promotion
Journal of Drug Issues 1992;22:235-243
HSL4867
Murphy MN, Smith MC, Juergens JP.
The synergic impact of promotion intensity and therapeutic novelty on market performance of prescription drug products
Journal of Drug Issues 1992;22:305-316
HSL4891
Peeler CL.
Pharmaceutical advertising: A Federal Trade Commission perspective
Journal of Pharmaceutical Marketing & Management 1992;7(1):157-167
HSL4893
Pines WL.
Trends in health care consumer communications
Journal of Pharmaceutical Marketing & Management 1992;7(1):87-98
HSL4895
Reynolds WJ.
Trends in advertising pharmaceuticals: A publisher's perspective
Journal of Pharmaceutical Marketing & Management 1992;7(1):5-22
HSL4903
Seaver PR.
Prescription drug advertising: An industry perspective
Journal of Pharmaceutical Marketing & Management 1992;7(1):33-41
HSL4907
Smith MC.
Future possibilities in pharmaceutical promotion
Journal of Drug Issues 1992;22:471-480
HSL4912
Stallings S.
From printing press to pharmaceutical representative: a social history of drug advertising and promotion
Journal of Drug Issues 1992;22:205-219
HSL4920
Vandewall J.
New directions in pharmaceutical advertising
Journal of Pharmaceutical Marketing and Management 1992;7(1):75-86
HSL4936
Wivell MK, O’fallon DA.
Drug overpromotion: when is a warning not a warning?
Trial 1992;28(11):20-27
HSL4938
Woolley RJ.
Pharmaceutical promotion
New England Journal of Medicine 1992;327:1687
HSL4774
Lexchin J.
Drug promotion: two views. Canada
INRUD News 1991 Dec;2(2):3
HSL4746
Huston P.
Surviving in a get-tough-on promotion climate
Medical Marketing & Media 1991 Jun;26(6):40-46, 48, 50-51
HSL4748
Sweeney HA.
Nothing has changed in 25 years
Medical Marketing & Media 1991 Jun;26(6):42
HSL4758
Randall T.
FDA scrutinizes 'off-label' promotions
JAMA 1991 Mar 7;266(1):11
HSL3131
Lee PR, Lurie P, Silverman MM, Lydecker M.
Drug promotion and labeling in developing countries: an update.
J Clin Epidemiol 1991;44
HSL4642
Arkinstall WW.
Medical ethics
Annals of the Royal College of Physicians and Surgeons of Canada 1991;24:161
HSL4663
Harvey K, Mansfield P.
Drug promotion: the critical approach
Australian Prescriber 1991;14(1):34-35
HSL4681
Mansfield PR.
Encouraging drug companies to be honest
Australian Prescriber 1991;14:74
HSL4694
Rapp MS.
A sample argument
Canadian Medical Association Journal 1991;144:118-119
HSL4708
Smith NC, Quelch JA.
Pharmaceutical marketing practices in the Third World
Journal of Business Research 1991;23:113-126
HSL4728
Winter DL.
Consensus reports from the convinced: Manipulating the information transfer process for drug promotion [reply]
JAMA 1991;265(1):30
HSL4516
Bushe CJ.
Ethical guidelines for promotion of prescription drugs to physicians
New England Journal of Medicine 1990;322:65
HSL4521
Chetley A.
A healthy business? World health and the pharmaceutical industry
Zed Books 1990
Link to source with long URL
HSL4530
Gall JM.
Medifacts tapes and general practice
Canadian Family Physician 1990;36:419
HSL4531
Gelbart H.
Doctors, drug companies, and gifts
JAMA 1990;263:2177
HSL4543
Jones K.
Advertising acyclovir
Lancet 1990;335:732
HSL4554
Strom B.
Notes of the American Society for Clinical Pharmacology and Therapeutics: Position paper on the use of purported postmarketing drug surveillance studies for promotional purposes
Clinical Pharmacology and Therapeutics 1990;48:598
HSL4565
Potter HP.
Physicians and the pharmaceutical industry
Annals of Internal Medicine 1990;113:407
HSL4578
Scherr L.
Physicians and the pharmaceutical industry
Annals of Internal Medicine 1990;113:408
HSL4589
Squires BP.
Editors and advertisers
Canadian Medical Association Journal 1990;143:167
HSL4591
Stein U.
Ginkgo biloba extracts
Lancet 1990;335:475-476
HSL4612
Secunda E.
Is TV addicted to drug company PR?
Business and Society Review 1990;73:11-14
HSL4457
Wade VA, Mansfield PR, McDonald PJ.
Drug companies' evidence to justify advertising.
Lancet 1989 Nov 25;2(8674):1261-3
HSL4492
MaLAM letter follow up—Merck Sharp & Dohme. Are MSD’s distributors uncontrollable?
MaLAM Newsletter 1989 Nov
HSL4486
Re: the promotion of DPT-P vaccine
1989 Oct
HSL4479
MaLAM letter follow-up—Merck Sharp & Dohme. Denial of responsibility
MaLAM Newsletter 1989 Jun
HSL4477
Drug utilization bibliography
1989 May
HSL4464
Re: the promotion of ketoconazole
1989 Feb
HSL4119
Adams DG.
FDA regulation of promotion of drugs: a legal primer
Drug Information Journal 1989;23:625-633
HSL4417
Harvey K.
Drug advertising
Medical Journal of Australia 1989;150:664-665
HSL4443
Montagne M.
Social exchange, values, and the marketing of pharmaceuticals
Journal of Pharmaceutical Marketing & Management 1989;3(3):45-55
HSL4489
Antidiarrhoeals again under attack
Scrip 1989(1457):29
HSL4103
Wells FO.
The code for promoting drugs.
BMJ 1988 Sep 10;297(6649):686-7
HSL4009
Kaufman JL.
Profligate medical marketing.
N Engl J Med 1988 Aug 25;319(8):522
HSL4013
Langman M.
The code for promoting drugs.
BMJ 1988 Aug 20-27;297(6647):499-500
HSL4068
Shaughnessy AF.
Drug promotion in a family medicine training center.
JAMA 1988 Aug 19;260(7):926
HSL4097
Re: the promotion of cefuroxime, cyanocobalamin, cephalexin, ranitidine and guaiphenesin
1988 Jun
HSL4088
Healthcare communications and pharmaceutical promotion
Health Horizons 1988 May(4):16-17
HSL1040
Mansfield P.
Diflunisal advertising.
Med J Aust 1988 Apr 18;148(8):418,
HSL4080
Re: the promotion of vitamins A & E
1988 Jan
HSL3987
Post-marketing surveillance by drug manufacturers
Lancet 1988;2:977
HSL4003
Heilman SR.
“A matter of influence”: graduate medical education and commercial sponsorship
New England Journal of Medicine 1988;318:53
HSL4031
Peay MY, Peay ER.
The role of commercial sources in the adoption of a new drug.
Soc Sci Med 1988;26(12):1183-9
Link to source with long URL
HSL4033
Pleil AM, Pathak DS.
Commercial drug compendium information: a First World/Third World comparison.
Int J Health Serv 1988;18(4):587-602
HSL4087
Mansfield PR.
Diflunisal advertising
Medical Journal of Australia 1988;148:418
HSL3934
Zuger A.
Promoting Retrovir.
N Engl J Med 1987 Oct 29;317(18):1160
HSL3875
Finucane T.
Drug company-sponsored symposia: pros and cons.
Am J Med 1987 Oct;83(4):811-2
HSL3902
Lexchin J.
Drug promotion.
N Z Med J 1987 Sep 23;100(832):603
HSL3974
The IFPMA code: how it works and how it’s working
International Federation of Pharmaceutical Manufacturers Associations 1987 Sep
www.ifpma.rog/hhhs/welcome.htm
HSL3869
Buckley EG.
Post-marketing surveillance of new drugs.
J R Coll Gen Pract 1987 Aug;37(301):337-8
HSL3972
IFPMA code: trivial requirements ignored by companies
1987 Aug:1
HSL3964
MaLAM letter follow up—Janssen
MaLAM Newsletter 1987 Jun:1-2
HSL3963
Piroxicam
1987 May:1-7
HSL3899
Laurence DR.
The academic clinical pharmacologist and the Royal College of Physicians Report on the relationship between physicians and the pharmaceutical industry.
Br J Clin Pharmacol 1987 Mar;23(3):253-5
HSL3936
Double standards—some improvements
HAI News 1987 Feb(33):1-2, 12
HSL3957
Re: the promotion of co-dergocrine
1987 Feb
HSL3929
Wilmshurst P.
An investigation by the ABPI (Association of the British Pharmaceutical Industry)
Lancet. 1987 Jan 10;1(8524):104
HSL3935
Hoechst a cause of illness? The pharmabusiness in the Third World
1987 Jan
HSL3872
Collier J, Herxheimer A.
Roussel convicted of misleading promotion
Lancet 1987;1:113-114
HSL3904
Lidstone J.
Marketing planning for the pharmaceutical industry
1987
HSL3914
Singleton SW.
Promoting Retrovir
New England Journal of Medicine 1987;317:1160
HSL3919
Squires BP.
In whose service?
Canadian Medical Association Journal 1987;137:983
HSL3921
Szuba TJ.
Drug promotion under the magnifying glass
Journal of Social and Administrative Pharmacy 1987;4:77-80
HSL3928
Weston-davies WH.
Advertising claims and the Medicines Act
Lancet 1987;1:278
HSL3933
Yellin AK.
FDA prescription drug enforcement policies and techniques
Food Drug Cosmetic Law Journal 1987;42:552-558
HSL3852
MLAM letter follow up—Pfizer
MLAM Newsletter 1986 Nov
HSL3759
Where to draw the line.
Lancet. 1986 Oct 11;2(8511):849
HSL3822
Smith R.
Doctors and the drug industry: too close for comfort.
Br Med J (Clin Res Ed) 1986 Oct 11;293(6552):905-6
HSL3846
Re: the promotion of amrinone
1986 Sep
HSL3847
Re: the promotion of furazolidone/kaolin/pectin
1986 Sep
HSL3841
Re: the promotion of piroxicam
1986 Aug
HSL3783
Greenhalgh T.
Drug marketing in the Third World: beneath the cosmetic reforms.
Lancet 1986 Jun 7;1(8493):1318-20
HSL3837
Re: the promotion of Rheopyrine
1986 Apr
HSL3834
Re: the promotion of ibuprofen syrup
1986 Feb
HSL3803
Mahood CB, Rothwell RP, Holford N.
Slow-release theophylline (THEO-24)
N Z Med J. 1986 Jan 22;99(794):21
HSL3931
Woods D.
Annual report to the readers
Canadian Medical Association Journal 1986 Jan 01;136(1):7
HSL3758
Need for a rational drugs policy
Lancet 1986;1:262
HSL3761
Anand MP.
Marketing drugs in the Third World
Lancet 1986;2:222
HSL3764
Bhattacharjee PK.
Marketing drugs in the Third World
Lancet 1986;2:576
HSL3768
Burley DM.
Should a drug company employee edit a medical journal?
Lancet 1986;1(801)
HSL3775
Comanor WS.
The political economy of the pharmaceutical industry.
J Econ Lit 1986;24(3):1178-1217
HSL3776
Drugs and the Third World: chloroform sale and hazards—a Malaysian study
Consumers’ Association of Penang 1986
HSL3784
Greenhalgh T.
Marketing drugs in the Third World
Lancet 1986;2:222
HSL3799
Lee A.
Marketing drugs in the Third World
Lancet 1986;2:222
HSL3804
Mamdani M, Walker G.
Essential drugs in the developing world
Health Policy and Planning 1986;1:187-201
HSL3821
Silverman M, Lee PR, Lydecker M.
Drug promotion: the Third World revisited.
Int J Health Serv 1986;16(4):659-67
HSL3748
Re: the promotion of vitamins A & E
1985 Sep 01
HSL3747
Re: the promotion of tetracycline
1985 Aug 01
HSL3742
Re: the promotion of pizotifen
1985 Jun 01
HSL3746
Re: the promotion of ampicillin (Binotal) in Indonesia
1985 Jun 01
HSL3743
Mansfield PR.
Protecting the innocent from harm: the Medical Lobby for Appropriate Marketing (MLAM)
New Doctor 1985 Jun(36):22-24
HSL3737
Re: the promotion of Lomotil
1985 Jan 01
HSL3706
WHO meeting agrees on rational drugs strategy
Lancet 1985;2:1350-1351
HSL3710
Collier J.
Ethics of drug marketing
Lancet 1985;1:166-167
HSL3711
Curran V, Golombok S.
Bottling it up
1985
HSL3713
Eastman HC.
Report of the commission of inquiry on the pharmaceutical industry
1985
HSL3723
Mackowiak JI, Gagnon JP.
Effects of promotion on pharmaceutical demand.
Soc Sci Med 1985;20(11):1191-7
HSL3733
Van DER.
Marketing myths: selling drugs in the Third World
Medicine in Society 1985;2(2):41-45
HSL3627
Collier J.
Unconvincing reassurance from the ABPI.
Lancet 1984 Dec 1;2(8414):1280
HSL3692
Re: the promotion of Binotal
1984 Dec 01
HSL3664
Yudkin JS.
Use and misuse of drugs in the Third World.
Dan Med Bull 1984 Nov;31
HSL3651
Rawlins MD.
Doctors and the drug makers.
Lancet 1984 Oct 6;2(8406):814
HSL3637
Kunin CM.
The relation between clinical investigators and the pharmaceutical industry.
Rev Infect Dis 1984 Jan-Feb;6(1):129-31
HSL3616
MLAM
Lancet 1984;2:861
HSL3617
Organon censured for marketing of anabolic steroids in developing countries
Lancet 1984;1:155
HSL3620
Bass MJ.
Chairman’s chair: research or marketing?
Family Medicine Research Update 1984;3(2):6-7
HSL3638
Laporte JR, Porta M, Capella D, Arnau JM.
Drugs in the Spanish health system.
Int J Health Serv 1984;14(4):635-48
HSL3650
Philbrook FA.
‘Misleading’ drug ad
Canadian Family Physician 1984;30:272, 274
HSL3656
Timmers R.
Legibility of advertisements
Lancet 1984;2:1396
HSL3658
Turner J.
World health assembly
Lancet 1984;1:1172-1173
HSL3659
Transnational corporations in the pharmaceutical industry of developing countries
1984
HSL3662
Wright T.
Legibility of advertisements
Lancet 1984;2:1396
HSL3663
Yarrow M.
Doctors and the drug makers
Lancet 1984;2:405
HSL3571
Avorn J, Soumerai SB.
A new approach to reducing suboptimal drug use.
JAMA 1983 Oct 7;250(13):1752-3
HSL3569
Pharmaceutical policies for the Third World--whose responsibility.
Lancet 1983 Jul 16;2(8342):144
HSL3576
Brooks PM, Birkett D.
Release of new drugs. The lessons of benoxaprofen
Med J Aust. 1983 Mar 19;1(6):251-2
HSL3584
Harvey K.
Promotion of newer antimicrobial agents.
Med J Aust 1983 Jan 8;1(1):27-8
HSL3591
Osifo NG.
Overpromotion of drugs in international product package inserts.
Trop Doct 1983 Jan;13(1):5-8
HSL3573
Beardshaw V.
Prescription for change: Health Action International’s guide to rational health projects
1983
HSL3579
Deitch R.
The government and the activities of the pharmaceutical industry
Lancet 1983;2:1432-1433
HSL3588
McAuley RG, Little F.
Junk mail
Canadian Medical Association Journal 1983;129:1174, 1176
HSL3590
O’Connor JF.
Research, critical thinking and the pharmaceutical industry
Nova Scotia Medical Bulletin 1983;62:66
HSL3600
Truth in drug advertising
Dispatch 1983(25):1-5
HSL3613
Gundry DRT.
The big spenders
British Medical Journal 1983;287:1884
HSL2425
Avorn J, Chen M, Hartley R.
Scientific versus commercial sources of influence on the prescribing behavior of physicians.
Am J Med 1982 Jul;73(1):4-8
Nil
HSL3533
Publicity and the public’s ‘right to know’
New Zealand Pharmacy 1982;2(6):19, 22
HSL3548
Muller M.
The health of nations: a north-south investigation
: Faber and Faber; 1982
HSL3528
Pazderka B, Rao RC.
Market share competition in the Canadian prescription drug industry: a comparison of several therapeutical markets
1981 Sep
HSL3514
Koumjian K.
The use of valium as a form of social control.
Soc Sci Med [E] 1981 Aug;15(3):245-9
HSL3524
Pharmaceutical prices in Canada: guiding principles for government policy
Pharmaceutical Manufacturers Association of Canada 1981 Feb
HSL3509
Gustafsson LL, Wide K.
Marketing of obsolete antibiotics in Central America.
Lancet 1981 Jan 3;1(8210):31-3
HSL3495
Journal IN.
Lancet 1981;2:801
HSL3496
Berry EM.
The evolution of scientific and medical journals
New England Journal of Medicine 1981;305:400-402
HSL3497
Blum R, Kreitman K.
Factors affecting individual use of medicines
1981:122-185
HSL3513
Jayasuriya DC.
Regulating the drug trade in the Third World
World Health Forum 1981;2:423-426
HSL3522
Silverman M, Lydecker M.
The promotion of prescription drugs and other puzzles
1981:78-92
HSL3492
Siskind V.
Prescription drug advertising
Medical Journal of Australia 1980 Jun 14;67:615, 617
HSL3473
Johnston TS.
Provision of medicines in Ecuador.
Lancet 1980 May 17;1(8177):1073-4
HSL1891
Palmisano P, Edelstein J.
Teaching drug promotion abuses to health profession students.
J Med Educ 1980 May;55(5):453-5
HSL3491
Woody E Jr.
The paradox of pharmaceutical advertising.
J Med Assoc Ga 1980 May;69(5):379
HSL3471
Hutchinson G.
Prescribing drugs—generic vs trade names
McGill Medical Journal 1980;46(1):2-6
HSL3472
Hymans R.
Trade displays at medical conferences
New Zealand Medical Journal 1980;92:329-330
HSL3487
Yudkin JS.
The economics of pharmaceutical supply in Tanzania.
Int J Health Serv 1980;10(3):455-77
HSL3459
Chapman S.
Prescription drug advertising
Medical Journal of Australia 1979 Nov 29;66:700
HSL3458
Ferris JD.
Prescription drug advertising
Medical Journal of Australia 1979 Nov 17;66:550
HSL3440
Schwartz H.
Junk mail.
N Engl J Med 1979 Jul 5;301(1):53
HSL3441
Snead OC.
Junk mail.
N Engl J Med 1979 Jul 5;301(1):53
HSL3422
Editor .
Publicity about sulindac [Editor's reply]
New England Journal of Medicine 1979;300(13):735
HSL3431
Mallace AH.
Publicity about sulindac [2nd of 4 letters]
New England Journal of Medicine 1979;300(13):734
HSL3410
Ahmad S, Sheikh AI, Meeran MK.
Publicity about sulindac [1st of 4 letters]
New England Journal of Medicine 1978;300(13):734
HSL3418
Blakeslee A.
Publicity about sulindac [4th of 4 letters]
New England Journal of Medicine 1978;300(13):735
HSL3295
Achong MR.
Use of cephalosporins.
Can Med Assoc J 1976 Nov 6;115(9):841
HSL3329
Hodes B.
Are magazine ads for O-T-C drugs based on fact?
J Am Pharm Assoc 1976 Sep;16(9):513-5
HSL3307
Keele G.
A survey of the effects of a drug promotion campaign.
J R Coll Gen Pract 1976 May;26(166):382-3
HSL3301
Eaton G, Parish P.
General practitioners' views of information about drugs.
J R Coll Gen Pract 1976;26
HSL3309
McCaffery M.
About those drug ads . . .
Canadian Family Physician 1976;22:110
HSL3315
Schwartzman D.
Promotional expenditures
The Johns Hopkins University Press 1976:182-211
HSL3331
Brooke P.
Promotional parameters: a preliminary examination of promotional expenditures
Journal of Drug Issues 1976;6(1):21-27
HSL3335
Halberstam M.
The other side of the coin: another physician views drug advertising
Journal of Drug Issues 1976;6(1):9-12
HSL3339
Pekkanen J.
The impact of promotion on physicians' prescribing patterns
Journal of Drug Issues 1976;6(1):13-20
HSL3341
Rucker TR.
Drug information for practitioners: commercial obligation or social responsibility?
Journal of Drug Issues 1976;6(1):43-49
HSL3285
Jacoby J, Small C.
The FDA approach to defining misleading advertising
Journal of Marketing 1975 Oct;39:65-73
HSL3273
Huse KD.
Medical advertising—the other side of the coin
Patient Management 1975;4(6):36-37
HSL3274
Kales A, Kales JD.
Shortcomings in the evaluation and promotion of hypnotic drugs
New England Journal of Medicine 1975;293:826-827
HSL3280
Telser L, Best W, Egan JW, Higinbotham HN.
The theory of supply with applications to the ethical pharmaceutical industry
Journal of Law and Economics 1975;18:449-478
HSL3282
Responsible advertising
Medical Journal of Australia 1975;62:90
HSL3269
Dryden A.
PMAC setting up board to pre-clear ads
Maclean Hunter 1974 Nov 18;79:3
HSL3238
Erill S.
Clinical pharmacology in Spain.
Clin Pharmacol Ther 1974 Sep;16(3):597-604
HSL3255
Gould D.
Can we handle modern drugs?
New Scientist 1974 May 23;62(899):460-1
HSL3240
Hay DR.
Postal pollution
New Zealand Medical Journal 1974;80:464
HSL3249
Nelson G.
New laws are needed to regulate the drug industry
Journal of Drug Issues 1974;4:243-248
HSL3252
Turner J.
Weaknesses in the system of promoting and marketing drugs
Journal of Drug Issues 1974;4:260-263
HSL3257
Barclay WR.
The American Medical Association's policy on drug advertising
Journal of Drug Issues 1974;4:287-290
HSL3258
Berger AA.
Drug advertising and the "pain, pill, pleasure" model
Journal of Drug Issues 1974;4:208-212
HSL3231
Williams JD, Geddes AM.
Advertising of antibiotics.
Br Med J 1973 Jun 9;2(5866):613
HSL3223
Kunnes R.
Drugs and public policy: Poly-drug abuse: drug companies and doctors
American Journal of Orthopsychiatry 1973;43:530-2
HSL3233
Stetler CJ.
Patterns of prescription drug use: The role of promotion
Journal of Drug Education 1973;3(4):389-402
HSL2939
Kimmey JR.
Drug efficacy and a journal's responsibility.
Am J Public Health 1972 Apr;62(4):461-2
HSL2202
Barnes CJ, Holcenberg JS.
Student reactions to pharmaceutical promotion practices.
Northwest Med 1971 Apr;70(4):262-6
HSL2938
Greenblatt DJ, Shader RI.
Meprobamate: a study of irrational drug use.
Am J Psychiatry 1971 Apr;127(10):1297-303
HSL3210
Usdin G.
The coin needn't smell: A response to the Seidenberg thesis
Mental Hygiene 1971 Jan;55:32-35
HSL3208
Steele H.
Prices & proftis in the drug industry; an economist’s view.
New Physician 1971;20:146-159
HSL3209
Vernon J.
Concentration, promotion, and market share stability in the pharmaceutical industry
Journal of Industrial Economics 1971;19:246-266
HSL3167
Reekie WD.
Some problems associated with the marketing of ethical pharmaceutical products
Journal of Industrial Economics 1970 Nov 01;19:33-49
HSL3135
Canadian doctors more sceptical of drug promotion than U.S. counterparts—report
Canadian Medical Association Journal 1970;102:884, 886
HSL861
Daniel EE, Leedham L.
Effect on student attitudes of a program of critical evaluation of claims for drugs.
J Med Educ 1966 Jan;41(1):49-60
HSL2415
Talalay P, Editor.
Drugs in Our Society.
Baltimore: John Hopkins Press; 1964
Link to source with long URL
HSL2393
Hopkins CC.
My Life in Advertising.
Chicago: 1996 reprint by NTC Business Books; 1927
http://books.mcgraw-hill.com/getbook.php?isbn=0844231010&template=
HSL2394
Hopkins CC.
Scientific advertising.
Chicago: 1996 reprint by NTC Business Books; 1923
http://books.mcgraw-hill.com/getbook.php?isbn=0844231010&template=
HSL2404
Bentham J, Dumont P, Bingham P.
Bentham's handbook of political fallacies
Baltimore: John Hopkins Press; 1824
Link to source with long URL
HSL860
Locke J.
An essay concerning human understanding
1690
http://etext.library.adelaide.edu.au/l/locke/john/l81u/index.html
HSL859
Aristotle.
Rhetoric.
Date uncertain
http://www.public.iastate.edu/~honeyl/Rhetoric/index.html